Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.

MLA

D’Andrea, David, et al. “Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.” The Journal of Urology, vol. 207, no. 1, Jan. 2022, pp. 70–76. EBSCOhost, https://doi.org/10.1097/JU.0000000000002190.

APA

D’Andrea, D., Black, P. C., Zargar, H., Dinney, C. P., Soria, F., Cookson, M. S., Montgomery, J. S., Kassouf, W., Dall’Era, M. A., Sridhar, S. S., McGrath, J. S., Wright, J. L., Thorpe, A. C., Holzbeierlein, J. M., Carrión, D. M., Di Trapani, E., Bivalacqua, T. J., North, S., Barocas, D. A., … Shariat, S. F. (2022). Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. The Journal of Urology, 207(1), 70–76. https://doi.org/10.1097/JU.0000000000002190

Chicago

D’Andrea, David, Peter C Black, Homayoun Zargar, Colin P Dinney, Francesco Soria, Michael S Cookson, Jeffrey S Montgomery, et al. 2022. “Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer.” The Journal of Urology 207 (1): 70–76. doi:10.1097/JU.0000000000002190.